# MabGenesis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mabgenesis

- Industry: Biotechnology
- Headquarters: Yokohama-shi, Japan
- Website: https://mabgenesis.com
- Total disclosed funding: $2.6M
- Latest round: Seed (Jun 1, 2020)
- Investors on record: 4

## About

Based in Japan, MabGenesis Inc. is a biopharmaceutical company dedicated to developing innovative therapies that address significant unmet medical needs in oncology and autoimmune diseases.Founded in 2019 in Yokohama-shi, Japan, MabGenesis Inc. focuses on creating advanced biopharmaceutical solutions. The company has completed 4 deals to date, with its most recent funding round occurring on December 24, 2024. Katsuhiro Shinjo serves as both the CEO and founder, having previously founded other ventures in the biopharmaceutical sector. In the latest funding round, MabGenesis raised JPY 470 million from investors including Axil Capital Partners, Long Black Partners, Miyazaki Taiyo Capital, and existing investor Regional Economy Vitalization Corporation of Japan (REVIC).MabGenesis specializes in the development of advanced biopharmaceutical products, primarily focusing on innovative therapies designed to address unmet medical needs in the fields of oncology and autoimmune diseases. Their core product offerings include monoclonal antibodies and biologics that target specific disease mechanisms, facilitating improved patient outcomes through personalized treatment approaches. These products have been meticulously engineered to engage with specific cellular pathways, effectively altering disease progression and enhancing the efficacy of existing treatment modalities. MabGenesis’s client base includes healthcare institutions, research organizations, and pharmaceutical companies, which utilize their products in clinical settings and research initiatives. The company's products are primarily marketed across North America and Europe, emphasizing their commitment to addressing healthcare challenges in these key regions.The revenue model for MabGenesis is structured around strategic partnerships and direct sales to healthcare providers. The company engages in B2B transactions, collaborating with hospitals and research labs to provide its innovative therapies. These transactions may include licensing agreements for proprietary technologies, enabling partner companies to incorporate MabGenesis's products into their own treatment regimens. Pricing strategies for these products are aligned with market standards for biopharmaceuticals, ensuring competitiveness while reflecting the advanced nature of their offerings. A significant portion of the revenue is generated from flagship products, which are integral to MabGenesis’s portfolio, contributing to a robust financial framework that supports ongoing research and development initiatives.In December 2024, MabGenesis Inc. raised JPY 470 million in venture funding to accelerate research, expand its antibody drug pipeline, and address growing medical needs in pets. The company plans to launch several new products in the coming years, targeting specific therapeutic areas within the oncology and autoimmune disease sectors. MabGenesis is also focused on expanding its market presence in Asia and Europe by 2025, leveraging the recent investment to enhance its operational capabilities and broaden its geographic reach.

## Funding rounds

- Seed, Jun 1, 2020, $2.2M — SMBC Venture Capital, Beyond Next Ventures, Miyagin Venture Capital, Anniversaire Holdings Inc
- Seed, Jan 19, 2019, $0.3M — Beyond Next Ventures

## Investors

- Beyond Next Ventures (https://capitalatlas.ai/funds/beyond-next-ventures) — Seed
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Seed
- Miyagin Venture Capital (https://capitalatlas.ai/funds/miyagin-venture-capital) — Seed
- Anniversaire Holdings Inc — Seed